Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;74(5):611-7.
doi: 10.1007/s40265-014-0204-x.

Ipragliflozin: first global approval

Raewyn M Poole  1 , Rosselle T Dungo
Affiliations

Ipragliflozin: first global approval

Raewyn M Poole et al. Drugs. 2014 Apr.

Abstract

Ipragliflozin (Suglat® [Japan]), an orally active, next-generation sodium-glucose transporter 2 (SGLT2) inhibitor, has been developed by Astellas Pharma and Kotobuki Pharmaceutical for the treatment of type 2 diabetes mellitus. Ipragliflozin has received its first global approval in this indication in Japan, for use as monotherapy or in combination with another antihyperglycaemic agent (metformin, pioglitazone, a sulfonylurea, an α-glucosidase inhibitor, a dipeptidylpeptidase-4 inhibitor or nateglinide). Ipragliflozin is the first SGLT2 inhibitor to be approved in Japan. This article summarizes the milestones in the development of ipragliflozin leading to this first approval for the treatment of type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Clin Drug Investig. 2013 Jul;33(7):489-96 - PubMed
    1. Curr Diab Rep. 2012 Jun;12(3):230-8 - PubMed
    1. J Diabetes Complications. 2013 May-Jun;27(3):268-73 - PubMed
    1. J Pharm Pharmacol. 2013 Mar;65(3):317-27 - PubMed
    1. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55 - PubMed

MeSH terms

LinkOut - more resources